On the other hand, the lack of induction of apoptosis by the T22-PE24-H6 in CXCR4+ CRC cells, both in vitro and in vivo, and the capacity of this nanotoxin to sequentially activate the pyroptotic markers NLRP3, caspase-1, and GSDMD, in CXCR4+ CRC cells, leading to its selective and CXCR4-dependent cell death, would establish this novel nanotechnological anticancer approach as a powerful alternative for the treatment of CRC tumors once they develop relapse and metastasize, especially, when recurrence is due to the upregulation of anti-apoptotic proteins (Hanahan & Weinberg, 2011) (Figure 5). The gene discussed is GSDMD; the disease is colorectal carcinoma.